IMMUNOHEMATOLOGY & TRANSFUSION MEDICINE
PAPER - III

Time : 3 hours
Max. Marks : 100

Important instructions:
- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:
1. a) Indications of Fresh Frozen Plasma. 5+5
   b) Factors affecting the quality of Fresh Frozen Plasma.

2. a) Define Massive Transfusion. 2+4+4
   b) What are the Massive Transfusion Protocols?
   c) How will you minimize the common side effects of Massive Transfusion?

3. a) Cryopreservation of peripheral blood stem cells. 5+5
   b) Factors affecting the quality of cryopreserved stem cells.

4. a) Functions of Hospital Transfusion Committee. 5+5
   b) How will you set up a programme for effective use of blood?

5. a) Pathogenesis of neonatal alloimmune thrombocytopenia. 5+5
   b) How will you investigate and treat a case of neonatal alloimmune thrombocytopenia?

6. a) What is therapeutic plasma exchange? 3+7
   b) Discuss Class 1 & 2 indications of therapeutic plasma exchange.

7. a) Discuss emerging new microbial contaminants of blood and blood products. 5+5
   b) Discuss various pathogen inactivation methods.

8. a) What is the pathogenesis of Transfusion Associated Acute Lung Injury (TRALI)? 5+5
   b) Discuss the strategies for prevention of TRALI.

9. a) What is haemovigilance? 2+3+5
   b) Compare and contrast French and British Hemovigilance programs
   c) Discuss positive effects of implementing hemovigilance program in developed countries.

10. a) Plan transfusion management in a newly diagnosed 5 years old thalassemia major patient. 5+5
    b) Discuss various clinical 8 laboratory parameters that need to be monitored in a thalassemia major patient who is on transfusions.

***************